Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia

BT Yilmaz, B Alioglu, E Ozyurek, HT Akay, S Mercan… - Pediatric …, 2005 - Springer
Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function
characterized by inappropriate bleeding that is difficult to control. Recombinant activated
factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical
support for these patients. This report describes the use of rFVIIa to prevent serious bleeding
during and after open-heart surgery in a child with Glanzmann thrombasthenia.
被引用次数：42 相关文章 所有 9 个版本
[PDF] researchgate.net

Successful Use of Recombinant Factor VIIa (NovoSeven®) During Cardiac Surgery in a Pediatric Patient with Congenital Factor XI Deficiency

Z Avci, B Malbora, M Gokdemir, S Ozkan, N Ozbek - Pediatric Cardiology, 2008 - Springer
We report our experience with the use of recombinant activated factor VII (rFVIIa) during
cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital
heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous
dose of rFVIIa (90 μg/kg) was administered. This same dosage was repeated eight more
times, at 2-to 4-hour intervals postoperatively. There was no bleeding during and after
surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in …
被引用次数：22 相关文章 所有 7 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果